Selinexor in Combination With Thalidomide and Dexamethasone in RRMM

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-06

Study Completion Date

2024-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multiple myeloma (MM) is an incurable plasma cell cancer that almost all patients eventually relapse despite advancement in treatment strategies. B-cell maturation antigen (BCMA) is a cell surface receptor that expressed primarily by malignant and normal plasma cells. This is a single-arm that includes escalation phase and expansion phase ,Selinexor in Combination withThalidomide and Dexamethasone to Treat Relapsed/Refractory Multiple Myeloma Patients.To evaluate efficacy and safety of Selinexor in combination with Thalidomide and Dexamethasone in RRMM patients received at least one prior lines of therapy

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM

NCT04941937

Multiple Myeloma

RECRUITING PHASE2

ATG-010(Selinexor) in Combination With Chemotherapy in RRMM

NCT04877275

Multiple Myeloma

RECRUITING PHASE2

Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement

NCT05478993

Multiple Myeloma

RECRUITING PHASE2

Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

NCT05422027

Multiple Myeloma

RECRUITING PHASE1/PHASE2

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma

NCT03944057

Relapse/Refractory Multiple Myeloma

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a single-arm and open-label phase Ib/IIa study of Relapsed/Refractory Multiple Myeloma patients who have received at least one prior lines of treatment therapy; Approximately 3-48 patients will be enrolled in the study. In dose escalation phase, patients with RRMM will be treated with thalidomide 100mg/d, dexamethasone 20mg biweekly, and escalating doses of oral ATG-010 weekly in a 3+3 design. ATG-010 dose level (DL) 1, 2 and 3 are 60, 80 and 100mg respectively.

Then a phase 2 expansion at the recommended dose level based on phase 1b trial will be conducted to evaluate the efficacy, safety and tolerability.

This arm is 4 weeks per cycle and include a total of 12 cycles.Selinexor RP2D，Thalidomide will be given at 100mg/d d1-28, and Dexamethasone 20 mg/d will be given on day 1, 2,8,9,15,16,22,23. If a patient develops partial intolerance to glucocorticoids (as determined by the Investigator) during the study, a dose reduction of dexamethasone maximum to 10 mg is permitted. If patients do not tolerate this dose, a potential discontinuation or further dose reduction would be allowed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Selinexor in combination with thalidomide and Dexamethasone

Selinexor in combination with thalidomide and Dexamethasone. Thalidomide will be given at 100mg/d d1-28,and Dexamethasone 20 mg/d will be given on day 1, 2,8,9,15,16,22,23. Treatment will be administered in 28-day cycles,include a total of 12 cycles. Selinexor dose escalation: 60, 80, 100mg respectively on day 1,8,15,22 for 4-week cycles. Then Selinexor will be given at the recommended dose level on phase II.

Group Type EXPERIMENTAL

Selinexor

Intervention Type DRUG

Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.

Thalidomide

Intervention Type DRUG

100mg/d, Po. on day1-28

Dexamethasone

Intervention Type DRUG

20 mg/d Po. on day 1, 2,8,9,15,16,22,23

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Selinexor

Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.

Intervention Type DRUG

Thalidomide

100mg/d, Po. on day1-28

Intervention Type DRUG

Dexamethasone

20 mg/d Po. on day 1, 2,8,9,15,16,22,23

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ATG-010 fǎn yìng tíng Dex

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Known and written informed consent (ICF) voluntarily.
2. Age ≥ 18 years and ≤ 75 years.
3. Patients with multiple myeloma who have received first-line treatment (induction, autologous transplantation and maintenance as the same first-line treatment) and achieved at least partial remission in induction.
4. At or after accepting first-line regimen, subjects must have progression disease (PD) recorded which is determined by researcher according to IMWG criteria.

Exclusion Criteria

6. Adequate hepatic function: total bilirubin \< 2× upper limit of normal (ULN) (for patients with Gilbert's syndrome, a total bilirubin of \< 3× ULN is required), AST \< 2.5× ULN, and ALT \< 2.5× ULN.
7. Adequate renal function: estimated creatinine clearance ≥ 20 mL/min (calculated using the formula of Cockroft-Gault).
8. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.
9. Measurable MM as defined by at least one of the following:

1. Serum M-protein (SPEP) ≥ 10 g/L
2. 24 hours-Urinary M-protein excretion ≥ 0.2 g (200 mg)
3. Serum FLC ≥ 100 mg/L with abnormal FLC ratio
10. Expected survival is more than 6 months.
11. Adequate hematopoietic function (no blood transfusion within 2 weeks and no G-CSF/GM-CSF supportive treatment within 1 week prior to screening test):

1. Hemoglobin level ≥ 80 g/L
2. ANC ≥ 1,000/mm3 (1.0×109/L)
3. Platelet count ≥ 75,000/mm3 (75×109/L)
12. Female patients of childbearing potential must meet below two criteria:

1. must agree to use effective contraception methods since signature in ICF, throughout the study and for 3 months following the last dose of study treatment.
2. must have a negative serum pregnancy test at screening. Note: A woman is considered of childbearing potential following menarche and until becoming postmenopausal (defined as no menstrual period for a minimum of 12 months) or permanently sterile (having undergone a hysterectomy, bilateral salpingectomy or bilateral oophorectomy). A woman who is taking oral contraceptive or using intrauterine device is considered of childbearing potential.
13. Male patients (including those who have received vasectomy) must use a condom if sexually active with a female of child-bearing potential throughout the study and for 3 months following the last dose of study treatment.

* Patients who meet any of the following criteria will not be enrolled:

1. Asymptomatic (smoldering) MM.
2. Plasma cell leukemia.
3. Documented active amyloidosis.
4. Previously refractory or intolerant to immunomodulators.
5. Pregnancy or breastfeeding.
6. Major surgery was performed within 4 weeks prior to the first study.
7. Patients with active, unstable cardiovascular diseases, fits any of the following:

1. Symptomatic ischemia, or
2. Uncontrolled clinically-significant conduction abnormalities (e.g., patients with ventricular tachycardia on antiarrhythmics are excluded; patients with first-degree atrioventricular (AV) block or asymptomatic left anterior fascicular block/right bundle branch block (LAFB/RBBB) are allowed), or
3. Congestive heart failure (CHF) of New York Heart Association (NYHA) ≥ Grade 3, or
4. Acute myocardial infarction (AMI) within 3 months prior to the first dose of study drug.
8. Uncontrolled active infection within 1 week prior to the first dose of study drug.
9. Known HIV positive.
10. Known active hepatitis A, B, or C infection; or known positive for HCV RNA or HBsAg.

(Note: patients with HBsAg negative but HBc Ab positive need further HBV-DNA test, excluded if HBV-DNA ≥103 , if HBV-DNA \<103 need anti-viral drugs)
11. Prior malignancy that required treatment or has shown evidence of recurrence (except for skin basal-cell carcinoma and in-situ carcinoma including squamous cell carcinoma, bladder cancer in situ, endometrial cancer in situ, cervical cancer in situ/atypical hyperplasia, prostate cancer incidental finding (T1a or T1b), or breast cancer in situ) within 5 years prior to the first dose of study drug.
12. Active GI dysfunction interfering with the ability to swallow tablets, or any GI dysfunction that could interfere with absorption of study treatment.
13. Grade ≥ 3 peripheral neuropathy, and Grade ≥ 2 painful neuropathy, within 3 weeks prior to the first dose of study drug.
14. Previous history of deep vein thrombosis.
15. Serious, active psychiatric, or medical conditions which, in the opinion of the Investigator, could interfere with study treatment.
16. Participation in an investigational anti-cancer clinical study within 3 weeks or 5 half-lives (T1/2) prior to the first dose of study drug.
17. Received ASCT within 12 weeks prior to the first dose of study drug or previous allogeneic stem cell transplantation (no time limitation).
18. Treatment with an approved or trial anticancer drug was given within 4 weeks prior to the first study.
19. Known intolerance to or contraindication for glucocorticoid therapy.
20. Prior exposure to a SINE compound.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No